A SEER-Medicare Based Quality Score for Patients With Metastatic Upper Tract Urothelial Carcinoma
Daniel Joyce(Vanderbilt University Medical Center), Vidit Sharma(University of California, Los Angeles), Karim Chamie(University of California, Los Angeles), Stephen B. Williams(Cedars-Sinai Medical Center), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Stephen A. Boorjian(Mayo Clinic), Courtney A. Stewart(The University of Texas Medical Branch at Galveston), Yong Shan(The University of Texas Medical Branch at Galveston)
Cited by 5
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus
|Journal of the American College of Cardiology|1996|1k